Ronald Crystal, MD
Pulmonary Disease · New York, NYNPI 1053408153
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $166,000 of the $212,823 with a category attached, or 78.0%. Biomarin Pharmaceutical Inc. accounts for 78.0% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $57,036 and has fallen 70.2% since, to $17,000 in 2024. Among pulmonary disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 47 payments — averaging $4528.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biomarin Pharmaceutical Inc.$166K
- Sarepta Therapeutics, Inc.$41K
- F. Hoffmann-la Roche AG$4K
- Zogenix Inc.$1K
- Eli Lilly$500
- Boehringer Ingelheim$87
Across 3 payments — averaging $224,448 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$350K
- Boehringer Ingelheim International GmbH$324K
What the payments were for
- Consulting fees$43,02020%
- Speaking & faculty fees$166,00078%
- Travel & lodging$3,3792%
- Food & beverage$4240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biomarin Pharmaceutical Inc. | 19 | $166,000 |
| Sarepta Therapeutics, Inc. | 23 | $41,266 |
| F. Hoffmann-la Roche AG | 1 | $3,920 |
| Zogenix Inc. | 2 | $1,050 |
| Eli Lilly | 1 | $500 |
| Boehringer Ingelheim | 1 | $87 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Brineura$166,000
- Exondys 51$12,856
- Fintepla$1,050
How this compares
$212,823 in reported general payments places this provider in the 95th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in New York
- Charles PowellNew York$654K
- Bisher AkilNew York$480K
- Sonali SethiNew York$388K
- Johnathan RaskinNew York$338K
- Monica KraftNew York$247K
- Jamie BessichNew York$226K
- Michael NiedermanNew York$176K
- Wilfredo TalaveraNew York$145K
- Josanna Rodriguez-LopezNew York$128K
- Kenneth BergerNew York$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.